Sanofi (FRA:SNW)
Germany
· Delayed Price · Currency is EUR | Market Cap | 109.29B |
| Revenue (ttm) | 45.17B |
| Net Income (ttm) | 6.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.04 |
| PE Ratio | 17.35 |
| Forward PE | 10.85 |
| Dividend | 3.92 (4.30%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 666,935 |
| Average Volume | 28,276 |
| Open | 91.84 |
| Previous Close | 91.12 |
| Day's Range | 89.80 - 91.96 |
| 52-Week Range | 86.00 - 110.82 |
| Beta | n/a |
| RSI | 37.76 |
| Earnings Date | Apr 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025. “The first qu...
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit
Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label
Hawaii said on Friday it entered a $700 million settlement deal with pharmaceutical firm Bristol-Myers Squibb and units of French pharmaceutical company Sanofi in a case about warning labels related t...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
On Thursday, Novavax Inc. (NASDAQ: NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million . Higher product sales for the...
Sanofi: Investing in prevention builds Europe's health and competitiveness
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic ...
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd . (NYSE: TEVA) and Alvotech’s (NASDAQ: ALVO) Selarsdi (ustekinumab-aekn) injection as interchangeable with...
Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus
Stay updated on top pharmaceutical news: Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composi...
Sanofi becomes a pure play pharma after 50% stake sale in Opella
Sanofi (SNY) stock gains as the company transitions to a pure-play biopharma company with a €10B stake sale in Opella, its consumer healthcare business. Read more here.
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Sanofi 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Sanofi in conjunction with their 2025 Q1 earnings call.
Sanofi proposes annual dividend of €3.92, a hike of 4.26% from prior dividend
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.
EU pharma majors Sanofi, Roche trade flat after reiterated guidance
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
Sanofi beats top-line and bottom-line estimates; reaffirms FY25 outlook
Innate Pharma Announces €15M Investment by Sanofi
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025...
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.